Literature DB >> 11380314

Review article: acid suppression in the management of gastro-oesophageal reflux disease--an appraisal of treatment options in primary care.

R Jones1, P Bytzer.   

Abstract

Gastro-oesophageal reflux disease (GERD) is one of the most common conditions presenting to the primary care physician. Despite progress in understanding and treatment of the disease, strategies for capitalizing on these advances are less well developed. In many practices, H2-receptor antagonists still remain the most widely prescribed treatment for GERD, despite the availability of the more effective acid-suppressant proton pump inhibitors. This review examines the relative efficacies of acid-suppressant drugs in minimizing oesophageal acid exposure and outlines the evidence for the superiority of proton pump inhibitors over standard-dose H(2)-antagonists in symptom relief, erosion healing and prevention of relapse in GERD. Current prescribing patterns and considerations for the general practitioner are also examined. The availability and impact of over-the-counter H(2)-antagonists on the treatment of GERD and their relative cost-effectiveness vs. proton pump inhibitors are also addressed. A hierarchy of drug efficacy (full-dose proton pump inhibitor > half-dose proton pump inhibitor > high-dose H(2)-antagonist > standard-dose H(2)-antagonist or prokinetic) applies in principle to all GERD patients, (with or without oesophagitis). The most effective initial therapy for GERD is also likely to be the most cost-effective one, if treatment failure leads to higher utilization of medical resources. The application of these recommendations to the management of non-endoscoped GERD, endoscopy-negative GERD and low-grade oesophagitis as well as higher grade oesophagitis is also reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380314     DOI: 10.1046/j.1365-2036.2001.00985.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.

Authors:  K Størdal; G B Johannesdottir; B S Bentsen; P K Knudsen; K C L Carlsen; O Closs; M Handeland; H K Holm; L Sandvik
Journal:  Arch Dis Child       Date:  2005-09       Impact factor: 3.791

2.  A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.

Authors:  Takashi Ando; Haruki Kato; Naohito Sugimoto; Yasuyuki Nagao; Nobuyuki Seto; Hitoshi Hongo; Hirokazu Kajikawa; Yutaka Isozaki; Makoto Shimozawa; Yuji Naito; Norimasa Yoshida; Takashi Ishizaki; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

3.  Noncardiac chest pain--an Asia-Pacific survey on the views of primary care physicians.

Authors:  Ting Kin Cheung; Paul Wah Yonn Lim; Benjamin C Y Wong
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

Review 4.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Transoral incisionless fundoplication for treatment of gastroesophageal reflux disease in clinical practice.

Authors:  Bart P L Witteman; Rob Strijkers; Eva de Vries; Liza Toemen; José M Conchillo; Wim Hameeteman; Pieter C Dagnelie; Ger H Koek; Nicole D Bouvy
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

6.  Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial.

Authors:  Per G Farup; Mathis Heibert; Victor Høeg
Journal:  BMC Complement Altern Med       Date:  2009-02-24       Impact factor: 3.659

7.  Management of laryngopharyngeal reflux with proton pump inhibitors.

Authors:  Christina Reimer; Peter Bytzer
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.